Siegfried Holding Ag · SIX:SFZN
Siegfried — Merger or Acquisition (June 2024)
10 slides from Siegfried's merger presentation, Jun 12, 2024
Slide 1: Siegfried to acquire an early-phase CDMO in Wisconsin (US)
Siegfried to acquire an early- phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering Zofingen, 12 June 2024
Slide 2: Safe harbor statement
Safe harbor statement This document is solely for use in connection with the presentation held by Siegfried Holding AG. It is furnished to you for your information and you may not reproduce it or redistribute to any other person. No representation or warranty, express or implied, is made to, and no
Slide 3: Siegfried to acquire early-phase CDMO in Wisconsin (US) from Curia
Siegfried to acquire early-phase CDMO in Wisconsin (US) from Curia Expanding customer offering in the US and strengthening service portfolio globally − Siegfried to acquire a CDMO specialized in early-phase development and manufacturing services in Grafton, Wisconsin (US), from Curia − The new site
Slide 4: Acquisition taps into the strong clinical pipeline of small molecules
Acquisition taps into the strong clinical pipeline of small molecules Small & medium-sized companies drive majority (>80%) of pre-clinical and early-phase projects New drug approvals by US FDA Total # of small molecules projects and products 59 Governmental/ university/ 75% 25% 1,181 55 non-profit 5
Slide 5: Capturing attractive opportunities already at early clinical stages
Capturing attractive opportunities already at early clinical stages Customers will benefit from synergies across all development phases all the way to commercial production Launch, Pre-clinical Discovery Ph-II Ph-III life cycle / Ph-I mgmt. − Out of Siegfried‘s − Increasing number of − To date, typi
Slide 6: Acquisition will be an additional feeder into our world-class network
Acquisition will be an additional feeder into our world-class network Mutually leveraging complementary capacities New business Process research & dev. centers Large-scale manufacturing network Pre-clinical or Grafton clinical products Pilot − Dual MDN sources for security of supply ZOF ZOF STV Pilo
Slide 7: We continue to deliver our strategy EVOLVE
We continue to deliver our strategy EVOLVE Grafton will further accelerate our growth story Grow existing core Add adjacencies Enter and grow new areas - Small molecule DS and DP - Formulation and aseptic fill - DS Antibodies & finish of large molecules - Complex chemistry - Cell & gene therapy (CGT
Slide 8: Siegfried
Siegfried
Slide 9: Thank you for your attention
22 August 2024 H1 Results 24 October 2024 Capital Markets Day Thank you for your attention 9 | |
Slide 10: Learn more about Siegfried
Learn Download our Annual Reports Visit our investors portal Learn more about Siegfried’s offering more about Siegfried Read more Read more Read more 10 | |
Siegfried Holding — Merger or Acquisition (June 2024) on 6ix